Welcome to our dedicated page for EyePoint news (Ticker: EYPT), a resource for investors and traders seeking the latest updates and insights on EyePoint stock.
The EyePoint, Inc. (EYPT) news page on Stock Titan aggregates company-reported updates and market-moving announcements for this clinical-stage biopharmaceutical business focused on serious retinal diseases. EyePoint’s disclosures emphasize its lead investigational product, DURAVYU™ (vorolanib intravitreal insert), and its progress through late-stage clinical development, making corporate news particularly relevant for investors tracking ophthalmology and retinal therapeutics.
Visitors can review news covering clinical milestones, such as enrollment completion and data safety monitoring committee recommendations for the Phase 3 LUGANO and LUCIA trials in wet age-related macular degeneration (wet AMD), as well as the design and initiation of the pivotal Phase 3 COMO and CAPRI trials in diabetic macular edema (DME). Company releases also highlight Phase 2 data from the DAVIO 2 and VERONA studies, which EyePoint cites as demonstrating meaningful and sustained improvements in vision and anatomy with favorable safety profiles.
In addition to clinical trial updates, EyePoint’s news includes financing and corporate developments, such as underwritten public offerings, at-the-market equity programs, and inducement grants under Nasdaq Listing Rule 5635(c)(4). These items provide context on how the company funds its DURAVYU programs and earlier-stage pipeline initiatives. Investors can also follow announcements about conference presentations at major healthcare and ophthalmology meetings and investor conferences, where EyePoint discusses its clinical data, trial designs, and development strategy.
By monitoring the EYPT news feed, readers can see how EyePoint communicates progress on its investigational sustained-delivery approach, interactions with regulators, and key risk disclosures referenced in forward-looking statements. This page is useful for those who want a centralized view of EyePoint’s official announcements, ranging from clinical milestones and safety updates to capital-raising activities and corporate governance events.
EyePoint Pharmaceuticals (NASDAQ: EYPT) reported positive results from its preclinical toxicology study of EYP-1901, a six-month sustained delivery treatment for wet age-related macular degeneration (AMD). No adverse findings related to EYP-1901 were observed, and key ocular measurements remained stable. The company plans to file for Investigational New Drug (IND) status by the end of 2020 and initiate a Phase 1 clinical trial in early 2021. EYP-1901 aims to offer a long-term treatment option for wet AMD, with potential future applications in diabetic retinopathy.
On November 19, 2020, EyePoint Pharmaceuticals (NASDAQ: EYPT) announced a virtual roundtable discussion on December 4, 2020, at 12:00 p.m. ET, focusing on local drug delivery for wet age-related macular degeneration (AMD) and EYP-1901, a potential six-month sustained delivery therapy. Esteemed retina specialists, including Robert Avery, M.D., and Elias Reichel, M.D., will participate. Interested parties can access the event by phone or via a live webcast on the company's website.
EyePoint Pharmaceuticals (NASDAQ: EYPT) announced positive data for its ophthalmic products YUTIQ and DEXYCU during the American Academy of Ophthalmology (AAO) 2020 Virtual Annual Meeting. The second Phase 3 trial for YUTIQ showed a significantly lower recurrence rate of uveitis (46.5% vs. 75%). A multicenter study confirmed DEXYCU's effectiveness in reducing inflammation after cataract surgery, while a comparison study indicated DEXYCU's superiority over traditional eye drops in pain control and patient preference. These findings support the long-term advantages of both products.
On November 10, 2020, EyePoint Pharmaceuticals (NASDAQ: EYPT) announced four abstracts featuring its products YUTIQ® and DEXYCU® presented at the American Academy of Ophthalmology (AAO) 2020 Virtual Annual Meeting from November 13-15, 2020.
The presentations include:
- YUTIQ: Phase 3 trial results showing 36-month anti-inflammatory activity.
- DEXYCU: Studies on patient preference and anti-inflammatory efficacy.
These advancements underline EyePoint's commitment to innovative ophthalmic solutions.
EyePoint Pharmaceuticals reported total revenues of $15.7 million for Q3 2020, a significant increase from $2.5 million in Q3 2019. The net product revenues reached $5.8 million with $3.5 million from YUTIQ and $2.3 million from DEXYCU. Customer demand surged over 120% for DEXYCU and over 5% for YUTIQ. The company is on track to file an IND for EYP-1901, targeting wet AMD, by year-end. Cash reserves stood at $30.5 million. A debt facility amendment waiving certain revenue covenants was also announced.
EyePoint Pharmaceuticals (EYPT) will release its third quarter 2020 results on November 5, 2020, followed by a conference call at 8:30 AM ET. The call can be accessed via phone or a live webcast on their corporate website. EyePoint is focused on developing innovative ophthalmic products, including DEXYCU®, the first approved intraocular treatment for postoperative inflammation, and YUTIQ®, a three-year treatment for chronic non-infectious uveitis. Their pipeline includes EYP-1901, targeting wet age-related macular degeneration.
EyePoint Pharmaceuticals (NASDAQ: EYPT) announced an amendment to its debt facility with CRG Servicing, waiving the net product revenue covenant for DEXYCU® and YUTIQ® for the year ending December 31, 2020. The revenue covenant for December 31, 2021, is reduced from $80 million to $45 million, reflecting a recovery in customer demand post-COVID-19. As of September 30, 2020, the company had approximately $28.7 million in cash. This amendment acknowledges encouraging recovery trends in customer demand and commercial progress.
EyePoint Pharmaceuticals (EYPT) reported estimated net product revenues for Q3 2020 between $5.5 and $5.9 million, a significant increase from $3.7 million in Q2 2020, as healthcare facilities resumed operations after COVID-19 closures.
Driving this growth was customer demand for YUTIQ and DEXYCU, with estimated revenues of $3.4-$3.5 million and $2.1-$2.4 million respectively. Demand for YUTIQ units increased to 450, while DEXYCU saw a rise to 4,700 units in Q3 2020.
EyePoint Pharmaceuticals (NASDAQ:EYPT) will have CEO Nancy Lurker present at two virtual conferences this September. The Cantor Virtual Healthcare Conference is scheduled for September 15 at 4:40 PM Eastern Time, followed by the H.C. Wainwright 22nd Annual Global Investment Conference on September 16 at 2:00 PM Eastern Time. A live webcast and replay will be accessible on their Investors page for 90 days. EyePoint specializes in innovative ophthalmic products, with commercial offerings including DEXYCU® and YUTIQ®, as well as pipeline developments using their Durasert® technology.
EyePoint Pharmaceuticals (NASDAQ: EYPT) has entered a purchase and marketing agreement with Vantage Outsourcing for its ophthalmic product DEXYCU®, enabling broader access in over 25 states. This collaboration aims to integrate DEXYCU into surgical protocols for treating ocular inflammation related to cataract surgery. President Nancy Lurker emphasizes the partnership's potential for expanding their reach within the cataract surgery market. Vantage Outsourcing's services will enhance the postoperative experience for patients by providing a long-lasting anti-inflammatory treatment.